Caspase-1-Inhibitor AC-YVAD-CMK Inhibits Pyroptosis and Ameliorates Acute Kidney Injury in a Model of Sepsis
Overview
Biotechnology
General Medicine
Authors
Affiliations
Objective: To observe the protective effect of AC-YVAD-CMK on sepsis-induced acute kidney injury in mice and to explore its possible mechanisms primarily.
Methods: Eighteen male C57BL/6 mice were randomly divided into sham-operated group (Control), cecal ligation and puncture group (CLP), and CLP model treated with AC-YVAD-CMK group (AC-YVAD-CMK) ( = 6 in each group). Mice were sacrificed at 24 h after operation, and blood and kidney tissue samples were collected for analyses. Histologic changes were determined microscopically following HE staining. The expression of Ly-6B and CD68 was investigated using immunohistochemistry. Serum concentrations of creatinine (sCR) and blood urea nitrogen (BUN) were measured. Serum levels of interleukin-1 (IL-1), interleukin-18 (IL-18), TNF-, and interleukin-6 (IL-6) were determined by ELISA. The expressions of Caspas-1, NLRP-1, IL-1, and IL-18 in renal tissues were investigated using Western blot. Immunofluorescence staining was used to detect the expression of GSDMD protein in renal tissues.
Results: AC-YVAD-CMK treatment significantly alleviates sepsis-induced acute kidney injury, with decreased histological injury in renal tissues, suppresses the accumulation of neutrophils and macrophages in renal tissues, and decreased sCR and BUN level ( < 0.05). Attenuation of sepsis-induced acute kidney injury was due to the prohibited production of inflammatory cytokines and decrease expression of Caspas-1, NLRP-1, IL-1, and IL-18 in renal tissues. In addition, AC-YVAD-CMK treatment significantly reduced the expression of GSDMD in renal tissues compared to those observed in controls ( < 0.05).
Conclusions: We demonstrated a marked renoprotective effect of caspase-1-inhibitor AC-YVAD-CMK in a rat model of sepsis by inhibition of pyroptosis.
Inflammasomes and idiopathic inflammatory myopathies.
Sun R, Chu J, Li P Front Immunol. 2024; 15:1449969.
PMID: 39723212 PMC: 11668653. DOI: 10.3389/fimmu.2024.1449969.
Islam M, Watanabe E, Salma U, Ozaki M, Irahara T, Tanabe S Front Immunol. 2024; 15:1493214.
PMID: 39720718 PMC: 11666431. DOI: 10.3389/fimmu.2024.1493214.
IL-18 biology in severe asthma.
Thawanaphong S, Nair A, Volfson E, Nair P, Mukherjee M Front Med (Lausanne). 2024; 11:1486780.
PMID: 39554494 PMC: 11566457. DOI: 10.3389/fmed.2024.1486780.
Resta S, Guerra F, Tala A, Bucci C, Alifano P Cells. 2024; 13(21.
PMID: 39513865 PMC: 11545737. DOI: 10.3390/cells13211758.
Taking AIM at Influenza: The Role of the AIM2 Inflammasome.
Xu D, Tate M Viruses. 2024; 16(10).
PMID: 39459869 PMC: 11512208. DOI: 10.3390/v16101535.